Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-5 of 5
Keywords: Calcitriol
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Secondary Hyperparathyroidism in Chronic Dialysis Patients: Results of the Italian FARO Survey on Treatment and Mortality
Available to PurchaseSubject Area:
Nephrology
Diego Brancaccio, Mario Cozzolino, Giuseppe Cannella, Piergiorgio Messa, Mario Bonomini, Giovanni Cancarini, Maria Rosa Caruso, Carmelo Cascone, Anna Maria Costanzo, Umberto di Luzio Paparatti, Sandro Mazzaferro, on behalf of the FARO Study Group
Journal:
Blood Purification
Blood Purif (2011) 32 (2): 124–132.
Published Online: 28 May 2011
... who received paricalcitol and/or cinacalcet (with or without VDRAs) compared with calcitriol showed a significant improvement in both all-cause and cardiovascular-related mortality (p < 0.001). Cinacalcet with or without VDRAs was not associated with a further decrease of mortality hazard ratios...
Journal Articles
Subject Area:
Nephrology
Journal:
Blood Purification
Blood Purif (2010) 29 (2): 163–176.
Published Online: 08 January 2010
... Calcitriol Calcium flux Blood Purif 2010;29:163 176 DOI: 10.1159/000245924 Published online: January 8, 2010 Calcium Balance in Dialysis Is Best Managed by Adjusting Dialysate Calcium Guided by Kinetic Modeling of the Interrelationship between Calcium Intake, Dose of Vitamin D Analogues and the Dialysate...
Journal Articles
High Frequency of Marked Hyperphosphatemia during Intravenous Calcitriol Therapy in Hemodialysis Patients with Refractory Hyperparathyroidism
Available to PurchaseSubject Area:
Nephrology
Journal:
Blood Purification
Blood Purif (1996) 14 (3): 234–241.
Published Online: 30 October 2008
...E. Descombes; G. Vogel; J. Rosman; J.-P. Wauters Efficacy and safety of intermittent intravenous calcitriol therapy were studied in 8 chronic hemodialysis patients with marked hyperparathyroidism refractory to oral therapy with calcium salts and daily vitamin D. They were followed for 20 weeks (32...
Journal Articles
Effects of Calcitriol on Type 5b Tartrate-Resistant Acid Phosphatase and Interleukin-6 in Secondary Hyperparathyroidism
Available to PurchaseSubject Area:
Nephrology
Kuo-Cheng Lu, Chin-Feng Tseng, Chia-Chao Wu, Lai-King Yeung, Jin-Shuen Chen, Tsu-Yi Chao, Anthony J. Janckila, Lung T. Yam, Pauling Chu
Journal:
Blood Purification
Blood Purif (2006) 24 (5-6): 423–430.
Published Online: 21 December 2006
... interleukin-6 (IL-6) levels is also characteristic of end-stage renal disease. This study investigates the effects of intravenous calcitriol on serum bone resorptive markers, namely, type 5b tartrate-resistant acid phosphatase (TRACP5b) and IL-6 in patients with SHP. Methods: Intravenous calcitriol therapy...
Journal Articles
Proceedings: Pathogenesis and Treatment of Renal Osteodystrophy
Available to PurchaseSubject Area:
Nephrology
Journal:
Blood Purification
Blood Purif (2003) 21 (4-5): 318–326.
Published Online: 29 August 2003
..., increased osteoclastic and osteoblastic activity, and high levels of circulating parathyroid hormone (PTH) and adynamic bone disease characterized by low bone turnover and low levels of circulating PTH. Retention of phosphorus, decreased levels of calcitriol in blood, decreased levels of serum ionized...